Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23,229 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies.
Guarino MJ, Schneider CJ, Hosford MA, Brahmer JR, Rudin CM, Finckenstein FG, Philip-Norton RE, Lu H, Weber MR, Ettinger DS. Guarino MJ, et al. Among authors: lu h. Oncologist. 2009 Feb;14(2):119-24. doi: 10.1634/theoncologist.2008-0124. Epub 2009 Jan 31. Oncologist. 2009. PMID: 19182243 Free PMC article. Clinical Trial.
Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.
Ramalingam S, Forster J, Naret C, Evans T, Sulecki M, Lu H, Teegarden P, Weber MR, Belani CP. Ramalingam S, et al. Among authors: lu h. J Thorac Oncol. 2008 Mar;3(3):258-64. doi: 10.1097/JTO.0b013e3181653d1b. J Thorac Oncol. 2008. PMID: 18317068 Free article. Clinical Trial.
Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortium.
Trippett TM, Herzog C, Whitlock JA, Wolff J, Kuttesch J, Bagatell R, Hunger SP, Boklan J, Smith AA, Arceci RJ, Katzenstein HM, Harbison C, Zhou X, Lu H, Langer C, Weber M, Gore L. Trippett TM, et al. Among authors: lu h. J Clin Oncol. 2009 Oct 20;27(30):5102-8. doi: 10.1200/JCO.2008.20.8975. Epub 2009 Sep 21. J Clin Oncol. 2009. PMID: 19770383 Free PMC article. Clinical Trial.
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.
Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Neal J, Lu H, Cuillerot JM, Reck M. Lynch TJ, et al. Among authors: lu h. J Clin Oncol. 2012 Jun 10;30(17):2046-54. doi: 10.1200/JCO.2011.38.4032. Epub 2012 Apr 30. J Clin Oncol. 2012. PMID: 22547592 Clinical Trial.
23,229 results
You have reached the last available page of results. Please see the User Guide for more information.